Eddy Anglade, Tenpoint Therapeutics CEO

Ten­point Ther­a­peu­tics launch­es with $70M to re­store vi­sion with stem cell ther­a­pies and ‘re­pro­gram­ming’ med­i­cines

Al­though nu­mer­ous biotech com­pa­nies are de­vel­op­ing gene ther­a­pies to cor­rect eye­sight, these ap­proach­es large­ly re­quire the af­fect­ed cells to re­main in­tact — while many forms of vi­sion loss are caused by dead or dy­ing cells. That’s why a new start­up is bet­ting that ad­vances in stem cell bi­ol­o­gy will en­able treat­ments that re­store vi­sion by re­plac­ing or re­gen­er­at­ing vi­tal tis­sues lost to dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.